全文获取类型
收费全文 | 8323篇 |
免费 | 675篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 23篇 |
儿科学 | 295篇 |
妇产科学 | 269篇 |
基础医学 | 1165篇 |
口腔科学 | 92篇 |
临床医学 | 1337篇 |
内科学 | 1335篇 |
皮肤病学 | 131篇 |
神经病学 | 731篇 |
特种医学 | 182篇 |
外科学 | 778篇 |
综合类 | 121篇 |
一般理论 | 22篇 |
预防医学 | 1146篇 |
眼科学 | 256篇 |
药学 | 615篇 |
中国医学 | 11篇 |
肿瘤学 | 505篇 |
出版年
2024年 | 9篇 |
2023年 | 92篇 |
2022年 | 53篇 |
2021年 | 232篇 |
2020年 | 186篇 |
2019年 | 285篇 |
2018年 | 305篇 |
2017年 | 237篇 |
2016年 | 249篇 |
2015年 | 272篇 |
2014年 | 358篇 |
2013年 | 500篇 |
2012年 | 688篇 |
2011年 | 684篇 |
2010年 | 369篇 |
2009年 | 319篇 |
2008年 | 517篇 |
2007年 | 562篇 |
2006年 | 505篇 |
2005年 | 517篇 |
2004年 | 475篇 |
2003年 | 453篇 |
2002年 | 357篇 |
2001年 | 72篇 |
2000年 | 45篇 |
1999年 | 68篇 |
1998年 | 90篇 |
1997年 | 66篇 |
1996年 | 56篇 |
1995年 | 51篇 |
1994年 | 45篇 |
1993年 | 50篇 |
1992年 | 20篇 |
1991年 | 19篇 |
1990年 | 18篇 |
1989年 | 9篇 |
1988年 | 13篇 |
1987年 | 13篇 |
1986年 | 8篇 |
1985年 | 11篇 |
1984年 | 14篇 |
1983年 | 6篇 |
1982年 | 17篇 |
1981年 | 6篇 |
1980年 | 10篇 |
1978年 | 11篇 |
1977年 | 9篇 |
1974年 | 6篇 |
1973年 | 7篇 |
1969年 | 6篇 |
排序方式: 共有9014条查询结果,搜索用时 62 毫秒
81.
Iolo Madoc-Jones PhD MSc BA Hons CQSW Sarah Wadd PhD MSc BSc Lawrie Elliott PhD MA PG Cert Anne Whittaker PhD BSc Post Grad Dip RNMH RMN Laura Adnum PhD MSc BSc Ciara Close PhD MSc BSc Jennifer Seddon PhD MSc BSc Maureen Dutton Michelle McCann MA CQSW Fiona Wilson BA 《Health & social care in the community》2021,29(2):344-352
Cognitive Impairment (CI) screening is recommended for those engaged in harmful levels of alcohol use. However, there is a lack of evidence on implementation. This paper explores the barriers and facilitators to CI screening experienced across a service specifically for older drinkers. The findings draw on data gathered as part of an evaluation of a multilevel programme to reduce alcohol-related harm in adults aged 50 and over in five demonstration areas across the United Kingdom. It is based on qualitative interviews and focus groups with 14 service providers and 22 service users. Findings are presented thematically under the section headings: acceptability of screening, interpretation and making sense of screening and treatment options. It is suggested that engagement with CI screening is most likely when its fit with agency culture and its purpose is clear; where service providers have the technical skills to administer and discuss the results of screening with service users; and where those undertaking screening have had the opportunity to reflect on their own experience of being screened. Engagement with CI screening is also most likely where specific intervention pathways and engagement practices can be accessed to respond to assessed need. 相似文献
82.
83.
84.
Blyth PL 《Health facilities management》1994,7(4):44, 46, 48-44, 46, 50
85.
86.
Blyth PL 《Health facilities management》1995,8(9):48, 50, 52-48, 50, 54
87.
Michael J. Millward David R. Newell Kally Yuen Jane P. Matthews Kathryn Balmanno Christopher J. Charlton Lindsey Gumbrell Michael J. Lind Fiona Chapman Madeleine Proctor Dorothy Simmonds Brian M. J. Cantwell A. Hilary Calvert 《Cancer chemotherapy and pharmacology》1995,37(1-2):161-167
The pharmacokinetics and pharmacodynamics of prolonged oral etoposide chemotherapy were investigated in 15 women with metastatic breast cancer who received oral etoposide 100 mg as a single daily dose for up to 15 days. There was considerable interpatient variability in the day 1 pharmacokinetic parameters: area under the plasma concentration time curve (AUC) (0–24 h) 1.95±0.87 mg/ml per min (mean ± SD), apparent oral clearance 60.9±21.7 ml/min per 1.73 m2, peak plasma concentration 5.6±2.5 g/ml, time to peak concentration 73±35 min and half-life 220±83 min. However, intrapatient variability in systemic exposure to etoposide was much less with repeated doses. The intrapatient coefficient of variation (CV) of AUC for day 8 relative to day 1 was 20% and for day 15 relative to day 1 was 15%, compared to the day 1 interpatient CV of 45%. Neutropenia was the principal toxicity. Day 1 pharmacokinetic parameters were related to the percentage decrease in absolute neutrophil count using the sigmoidal Emax equation. A good fit was found between day 1 AUC and neutrophil toxicity (R
2=0.77). All patients who had a day 1 AUC>2.0 mg/ml per min had WHO grade III or IV neutropenia. The predictive performance of the models for neutrophil toxicity was better for AUC (percentage mean predictive error 5%, percentage root mean square error 18.1%) than apparent oral clearance, peak plasma concentration, or daily dose (mg/m2). A limited sampling strategy was developed to predict AUC using a linear regression model incorporating a patient effect. Data sets were divided into training and test sets. The AUC could be estimated using a model utilizing plasma etoposide concentration at only two time points, 4 h and 6 h after oral dosing (R
2=98.9%). The equation AUCpr=–0.376+0.631×C4h+0.336×C6h was validated on the test set with a relative mean predictive error of –0.88% and relative root mean square error of 6.4%. These results suggest monitoring of AUC to predict subsequent myelosuppression as a strategy for future trials with oral etoposide.Division of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Locked Bag 1, A'Beckett St, Melbourne 3000, Australia 相似文献
88.
89.
90.